Shots:
- The UK’s MHRA & Swissmedic have approved Nemluvio (SC) for mod. to sev. PN & AD, where it is approved in adults for PN & in combination with TCS ± TCI in pts (≥12yrs.; ≥30kg) for AD who are candidates for systemic therapy. Awaits approval in Singapore & Australia
- Approval is based on P-III (OLYMPIA for PN & ARCADIA for AD) trials that showed Nemluvio improved skin lesions, itch, & sleep disturbance in PN & AD pts with favorable safety
- Nemolizumab (mAb) targets IL-31 receptor alpha to inhibit IL-31 signaling, responsible for itch & other symptoms in mod. to sev. AD & PN
Ref: Businesswire | Image: Galderma
Related News:- Galderma’s Nemluvio (Nemolizumab) Secures the EU Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD) and Prurigo nodularis (PN)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
